With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat these disorders.

Roche Forms Partnership Worth Potentially More than $1 Billion with Innovent to Develop Novel ADC for SCLC

By Feliza Mirasol

January 3rd 2025

Under the agreement, the companies will advance development of IBI3009, Innovent’s ADC candidate, which has received IND approvals in the US, China, and Australia.

Prasinezumab Misses Primary Endpoint in Roche’s Phase IIb Study, but Has Potential in Treating Early Stage Parkinson’s Disease

By Feliza Mirasol

December 25th 2024

Results from a Phase IIb study missed the primary endpoint by failing to achieve statistical significance.

Orexo and Abera Partner to Develop Nasal Powder Vaccines

By Feliza Mirasol

December 20th 2024

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

AbbVie to Boost Immunology Pipeline with Acquisition of Nimble Therapeutics

By Feliza Mirasol

December 18th 2024

AbbVie's latest acquisition target is Nimble Therapeutics, which will give AbbVie a lead asset, an oral peptide for treating psoriasis.